BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chemotherapy in patients with HR+/HER2-low metastatic breast cancer. The overall survival data are not yet mature, and a higher incidence of interstitial lung disease was observed, mostly mild to moderate. The companies will review the data to decide next steps, noting the potential benefit may be limited given current treatment options. Trastuzumab Pamirtecan is also being tested in other cancer trials, including uterine cancer and advanced solid tumors.
BioNTech shares trade at USD 86.58 on Pluang as of Oct 26, 2026, 16:11 WIB, down 1.74% in one day. The stock's market cap stands at $22.13 billion with a 52-week range between $83.89 and $119.34. Volume is 838,377, reflecting active investor interest amid ongoing clinical developments.
BioNTech and DualityBio announced that their Phase 3 trial DYNASTY-Breast02 met its primary endpoint, showing a statistically significant but modest improvement in progression-free survival (PFS) for trastuzumab pamirtecan compared to chemotherapy in...
BioNTech and Bristol Myers Squibb reported promising Phase 2 results for pumitamig combined with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who progressed after immunotherapy plus chemotherapy. The treatment showed a confirmed ...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
BioNTech announced a collaboration with Gilead Sciences to test pumitamig combined with sacituzumab govitecan in a Phase 3 trial for PD-L1 low or negative triple-negative breast cancer (TNBC). This trial, ROSETTA Breast-01, will replace chemotherapy ...
